|Last Price$17.74||Day Change (%)-1.33%|
|Open Price$18.01||Day Change ($)-0.24|
|Day Range17.73–18.02||52-Week Range9.37–18.20|
As of Wed 12/11/2013 04:56 PM EST | USD
Four-Year Data from Phase 3 DASISION Trial Comparing Sprycel® (dasatinib) to Imatinib in First-Line Treatment of Adults with Ph+ CP-CML Presented at Annual Meeting of the American Society of Hematology
Favorable conditions are in place for merger-arbitrage ETFs, including increasing M&A activity and the likelihood of higher interest rates.
Morningstar analysts see pharmaceuticals as 2010's hot zone for mergers and acquisitions.
We'd prefer a pack of gum to these businesses.
Three ways to separate long-term winners from stocks that fizzle.